Listeria Meningitis Complicating Alemtuzumab Treatment in Multiple Sclerosis—Report of Two Cases

Alemtuzumab, a humanized monoclonal antibody targeting the surface molecule CD52, leads to a rapid depletion of immune cells in the innate and adaptive immune system. In phase 2 and 3 trials in multiple sclerosis (MS), infections have been reported more frequently in alemtuzumab than in interferon b...

Descripción completa

Detalles Bibliográficos
Autores principales: Rau, Daniela, Lang, Michael, Harth, Andreas, Naumann, Markus, Weber, Frank, Tumani, Hayrettin, Bayas, Antonios
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2015
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4519865/
https://www.ncbi.nlm.nih.gov/pubmed/26132570
http://dx.doi.org/10.3390/ijms160714669
Descripción
Sumario:Alemtuzumab, a humanized monoclonal antibody targeting the surface molecule CD52, leads to a rapid depletion of immune cells in the innate and adaptive immune system. In phase 2 and 3 trials in multiple sclerosis (MS), infections have been reported more frequently in alemtuzumab than in interferon beta treated patients. Here we report two patients treated with alemtuzumab for MS developing Listeria meningitis few days after the first infusion cycle. Both patients recovered completely after prompt diagnosis and adequate treatment. Physicians and patients should be aware of this serious, but treatable complication.

Ejemplares similares